scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Código da empresaSCPH
Nome da EmpresascPharmaceuticals Inc
Data de listagemNov 17, 2017
CEOMr. John H. Tucker
Número de funcionários162
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 17
Endereço25 Burlington Mall Road, Suite 203
CidadeBURLINGTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal01803
Telefone16175170730
Sitehttps://www.scpharmaceuticals.com/
Código da empresaSCPH
Data de listagemNov 17, 2017
CEOMr. John H. Tucker
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados